Increased Stem Cell Factor Release by Hemangioma-Derived Endothelial Cells by Meininger, C. J. et al.
Sacred Heart University
DigitalCommons@SHU
Biology Faculty Publications Biology Department
2-1995







Follow this and additional works at: http://digitalcommons.sacredheart.edu/bio_fac
Part of the Cell and Developmental Biology Commons, Laboratory and Basic Science Research
Commons, and the Medical Pathology Commons
This Article is brought to you for free and open access by the Biology Department at DigitalCommons@SHU. It has been accepted for inclusion in
Biology Faculty Publications by an authorized administrator of DigitalCommons@SHU. For more information, please contact
ferribyp@sacredheart.edu.
Recommended Citation




LABORATORY INVESTIGATION Vol. 72, No. 2, p. 166,1995 
Copyright © 1995 by The United States and Canadian Academy of Pathology, Inc. Printed in U.S.A. 
I n c r e a s e d S t e m C e l l F a c t o r R e l e a s e b y 
H e m a n g i o m a - D e r i v e d E n d o t h e l i a l C e l l s a 
C . J . M E I N I N G E R , S . E . B R I G H T M A N , K . A . K E L L Y , A N D B . R . Z E T T E R 
Microcirculation Research Institute, Department of Medical Physiology, Texas A&M University 
Health Science Center, College Station, Texas; Departments of Cellular and Molecular Physiology 
and Surgery, Harvard Medical School, Children's Hospital, Boston, Massachusetts; Department 
of Biology, Sacred Heart University, Fairfield, Connecticut 
BACKGROUND: Capillary hemangiomas, the most common tumors in young children, consist of 
proliferating capillary vessels and endothelial cells. These tumors also contain large numbers of 
mast cells, compared with the normal surrounding skin or tissue. We have recently shown that 
stem cell factor (SCF), the gene product of the murine steel locus, can act as a chemoattractant for 
mast cells. In this study, we investigated whether SCF might be involved in the recruitment and 
maintenance of mast cells in hemangiomas. 
EXPERIMENTAL DESIGN: Cultured endothelial cells derived from a murine hemangioma were 
compared with normal vascular endothelial cells for the ability to produce and release SCF, a 
mitogen for mast cells. 
RESULTS: Conditioned medium from hemangioma-derived endothelial cells stimulated the prolif-
eration of cultured mast cells. This proliferative activity was potentiated by interIeukin-3. The 
same conditioned medium was unable to stimulate proliferation of mast cells expressing a defective 
receptor for SCF. The medium was also unable to stimulate proliferation when it was preincubated 
with neutralizing antibodies specific for SCF. Immunoprecipitation and Western blot analysis of 
the conditioned media from hemangioma cells and normal endothelial cells demonstrated the 
31,000 molecular weight SCF in hemangioma-conditioned medium only. In addition, proliferative 
activity for mast cells could not be demonstrated in the conditioned medium of the normal 
endothelial cells, although Northern blot analysis indicated that both normal and hemangioma-
derived endothelial cells express SCF mRNA. Reverse transcriptase-polymerase chain reaction 
techniques were used to amplify the DNA sequence coding for the proteolytic cleavage site used 
for release of SCF. Results indicated that both normal and hemangioma-derived endothelial cells 
express the same transcript for SCF. 
CONCLUSIONS: Our data suggest that increased release of SCF is a property of hemangioma-
derived endothelial cells that may account for the high numbers of mast cells observed in heman-
gioma tissue. This increased release of SCF is not due to alternate splicing of SCF transcripts by 
hemangioma cells. 
Additional key words: Mast cells, Steel factor, kit ligand, Mast cell growth factor, Angiogenesis. 
Hemangiomas, the most common tumors of infancy, Hemangiomas consist of an irregular proliferation of 
vary from small, innocuous marks to mutilating, and in capillary vessels and/or endothelial cells. They charac-
some cases life-threatening, lesions. Small hemangiomas teristically exhibit a period of rapid proliferation followed 
may impinge on vital structures, such as the cornea or by slow spontaneous involution and disappearance. In-
upper airways, whereas hemangiomas that grow to a large teresting to note, the presence of mast cells correlates 
size may actually distort adjacent structures and cause with the growth of this tumor. The density of mast cells 
functional impairment. Congestive heart failure often in rapidly growing hemangiomas is at least five times 
occurs with hepatic hemangiomatosis (1), and acute res- that of normal skin, and the density returns to normal 
piratory distress is a complication of subglottic heman- at the time of tumor regression (5, 6). The signal(s) 
giomas (2). Gastrointestinal bleeding and obstruction responsible for these changes in mast cell density have 
can occur as well as perforation of the small intestine not been explored. 
(3). A life-threatening thrombocytopenia with wide- Mast cells can exhibit directed motility (i.e., chemo-
spread hemorrhage (Kasabach-Merritt syndrome) may taxis). Mast cells migrate in response to tumor implan-
occur in association with a single enlarging hemangioma tation (7), tumor-derived peptides (8), matrix compo-
or diffuse hemangiomatosis (4), nents, such as laminin (9), and interleukin-3 (IL-3) (10). 
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re have also found that mast cells migrate in response 
to stem cell factor, a hematopoietic growth factor (11). 
Stem cell factor (SCF) (12), also known as mast cell 
growth factor (MCGF) (13) or kit ligand (14), is a potent 
stimulator of mast cell proliferation and can potentiate 
IL-3-induced proliferation. Using cells derived from a 
murine hemangioendothelioma (15), we investigated 
whether altered production or release of SCF might be a 
property of hemangiomas by comparing the amount of 
SCF produced and released by hemangioma-derived 
endothelial cells relative to normal endothelial cells. 
EXPERIMENTAL DESIGN 
Cultures of endothelial cells derived from murine he-
mangiomas, murine aorta, and murine lung and brain 
microvessels were established. Growth media condi-
tioned by these cells were tested for the ability to stim-
ulate bone marrow-derived mast cell proliferation, a 
characteristic of SCF. Confirmation of SCF identity was 
achieved by antibody neutralization of mitogenic activity 
as well as by immunoprecipitation followed by Western 
blot analysis. Northern analysis was used to indicate steady 
state levels of mRNA for SCF. Reverse transcriptase-
polymerase chain reaction techniques were used to de-
termine if the release of SCF was a function of alternative 
splicing of mRNA transcripts produced in these cells. 
RESULTS AND DISCUSSION 
To determine whether hemangioma cells produce and 
release a factor(s) that stimulate(s) the proliferation of 
mast cells, we tested the ability of medium conditioned 
by cells of a spontaneous hemangioma (EOMA cells) to 
stimulate the proliferation of cultured mast cells (Fig. 
LA). Undiluted conditioned medium produced a two to 
three-fold increase in mast cell proliferation relative to 
unstimulated controls. Dilution of the conditioned me-
dium reduced the proliferative response, indicating that 
the response was dose-dependent. The response to un-
diluted conditioned medium was equivalent to the re-
sponse of the mast cells to 10 ng/ml recombinant rat 
SCF (rrSCF). The proliferative response to conditioned 
medium was potentiated by the presence of 10 U/ml IL-3, 
as has been shown previously for purified SCF (12). 
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W42 mast cells possess a defective c-kit receptor tyro-
sine kinase and do not grow or migrate in response to 
SCF. As shown in Figure IB, these cells failed to prolif-
erate in the presence of EOMA-conditioned medium, 
suggesting that the proliferative activity is mediated via 
activity of the c-kit receptor. The result was not due to 
a general loss of proliferative potential in these cells; 
they demonstrated a normal proliferative response to 
IL-3. 
To verify that the proliferative activity in the condi-
tioned medium from the EOMA cells was due to the 
presence of SCF, the conditioned medium was preincu-
bated with antibody capable of neutralizing the activity 
of rrSCF. One hour of incubation with antibody was 
sufficient to completely abolish the proliferative activity 
in the conditioned medium or in control medium con-
taining 50 ng/ml rrSCF (Fig, 2). These results suggest 
that all of the mast cell stimulatory activity present in 
hemangioma cell-conditioned medium can be attributed 
to SCF. 
To determine whether normal endothelial cells also 
release SCF, conditioned media from the hemangioma-
derived (EOMA) and aortic (MAEC) endothelial cells 
were compared. Significant proliferative activity for 
cultured mast cells was noted only in the EOMA-
conditioned medium (Fig. 3). The proliferative response 
of the mast cells to EOMA-conditioned medium supple-
mented with 10 U/ml of IL-3 was significantly higher 
than the proliferative response to 10 U/ml of IL-3 alone, 
indicating that the proliferative response was not due 
merely to the presence of IL-3. No statistically signifi-
cant proliferative activity was noted in the conditioned 
medium from MAEC when tested alone or when supple-
mented with IL-3. 
Murine stem cell factor (kit Iigand-1 [KL-1]) is syn-
thesized as a 45 kD (248 amino acid)-membrane protein 
(13,14, 16,17). The membrane-bound form is processed 
by a serine protease at the cell surface (18). Proteolytic 
cleavage releases a soluble, biologically active form of 
stem cell factor with a molecular weight of approximately 
31 kD. This soluble protein is analogous to the isolated 
natural rat protein that has been completely sequenced 
and that contains 164 or 165 amino acids (19). Both rat 
DMEMIL-3 rSCF 10%50%100'K 
FBS C.M.C.M.C.M. 
FlG. 1. A Dose-dependent stimula-
tion of mast cell proliferation by EOMA 
conditioned medium. Cultured bone 
marrow-derived mast cells were incu-
bated with basal medium alone, basal 
medium containing 10 ng/ml rrSCF, or 
conditioned medium (CM.) from the he-
mangioendothelioma cells with (+) or 
without (-) 10 U/ml IL-3. Cell numbers 
were determined after 72 hours of incu-
bation. Data represent means ± SEM. B 
Failure of mutant mast cells to respond 
to EOMA conditioned medium. W42 
mast cells were incubated with basal me-
dium, with basal medium containing 
high levels of IL-3, with basal medium 
containing 100 ng/ml rrSCF and in var-
ious concentrations of EOMA condi-
tioned medium. Cell numbers were de-
termined after 72 hours of incubation. 
Data represent means ± SEM. 
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FIG. 2. Effect of anti-SCF antibodies on the mast cell proliferative 
activity in EOMA conditioned medium. Cultured bone marrow-derived 
mast cells were incubated with basal medium alone, or in basal medium 
containing 50 ng/ml rrSCF and EOMA conditioned medium preincu-
bated with (+) or without {—) polyclonal antibodies against rat SCF. 
Cell numbers were determined after 72 hours of incubation. Data 
represent means ± SEM. 
NEQ.CTHL 
IL-3 (10 U/ml) 
EOMA CM. 
EOMA C.M.+ IL-3 
B MAEC CM. 
• MAEC CM.+IL-3 
FIG. 3. Comparison of the mast cell proliferative activity in EOMA 
conditioned medium and medium conditioned by normal endothelial 
cells. Cultured bone marrow-derived mast cells were incubated with 
basal medium alone, basal medium containing 10 U/ml IL-3, or undi-
luted conditioned medium from EOMA or MAEC with or without 10 
U/ml IL-3. Cell numbers were determined after 72 hours of incubation. 
Data represent means ± SEM. 
and human SCF migrate over a range of molecular weight 
of 28,000 to 35,000 on sodium dodecyl sulfate (SDS) 
polyacrylamide gels because of extensive and heteroge-
neous glycosylation of the protein (19, 20). 
A protein with a molecular weight of approximately 
31,000 was precipitated from the conditioned medium of 
the EOMA cells (Fig. 4, lane 3). This same protein could 
not be precipitated from the conditioned medium of the 
MAEC (Fig. 4, lane 2), even though it was prepared from 
three times the number of cells used to generate condi-
tioned medium from the EOMA cells. The major bands 
at approximately 25 and 50 kD represent the light and 
heavy chains of the rabbit immunoglobulin that were 
dissociated from the Protein-A Sepharose (as visualized 
in Fig. 4, lane 1, containing fresh, nonconditioned 
medium subjected to immunoprecipitation). A second 
band appearing at approximately 45 kD in the EOMA-
conditioned medium has not been conclusively identified 
but may represent full-length SCF. 
Northern blot hybridization using a 32P-labeled cDNA 
probe specific for murine SCF revealed a single band of 
radioactivity at approximately 7.5 kb (Fig. 5). This 
mRNA for SCF was present in both the MAEC and 
EOMA cells. This suggests that both endothelial cell 
types have the ability to make SCF mRNA and, presum-
ably, SCF protein. Human umbilical vein endothelial 
cells have recently been shown to express SCF mRNA, 
although the existence of the protein in these cells was 









FlG. 4. Demonstration of stem cell factor in conditioned media of 
EOMA and normal endothelial cells. Conditioned media from EOMA 
and MAEC as well as fresh, nonconditioned medium were immunopre-
cipitated with rabbit anti-murine SCF and Protein-A Sepharose, sep-
arated by SDS polyacrylamide gel electrophoresis, blotted to nitrocel-
lulose, and probed with the same polyclonal antibody specific for SCF. 
Immunodetected proteins were visualized using a chemiluminescence 
detection system. Soluble SCF (molecular weight =s 31,000) is indicated 
by the arrow. Molecular weight standards (in kilodaltons) are also 
indicated at the left. Lane 1, fresh medium; lane 2, MAEC-conditioned 
medium; lane 3, EOMA-conditioned medium. 
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FIG. 5. Northern blot analysis of mRNA from EOMA and MAEC. 
Three micrograms of mRNA from EOMA and MAEC were separated 
on an agarose-formaldehyde gel, transferred to nylon membranes, 
hybridized with a a2P-labeled cDNA probe specific for murineSCF, and 
processed for autoradiography. 
Several growth factors are synthesized as transmem-
brane precursors that are proteolytically processed to 
generate soluble factors that function in juxtacrine and/ 
or paracrine stimulation. Colony stimulating factor-1 
(CSF-1), which is genetically and structurally related to 
SCF (22), has been shown to be cleaved proteolytically 
to produce a soluble growth factor (23, 24). Other mem-
brane growth factors include tumor necrosis factor a 
(TNFa) (25) as well as transforming growth factor a 
(TGFa) and several other members of the epidermal 
growth factor family (18). 
Little work has been done to examine the regulation 
of SCF expression and processing. Huang et al. (17) 
demonstrated that proteolytic cleavage of the membrane-
bound SCF in COS-1 transfected cells was stimulated by 
the protein kinase C inducer phorbol 12-myristate 13-
acetate and the calcium ionophore A23187, suggesting 
differential regulation of this process. The data presented 
here indicate an inherent difference between the endo-
thelial cells of the hemangioma and those found in the 
normal vasculature. The data suggest that hemangioma-
derived endothelial cells are able to release soluble SCF 
whereas normal endothelial cells are not. Both cell types 
make SCF and transport it to the cell surface, but only 
the hemangioma-derived cells appear to be able to release 
significant quantities of the soluble protein. 
Huang et al. (17) showed that the soluble form of SCF 
is generated by efficient proteolytic cleavage from a 
transmembrane precursor termed kit Iigand-1 or KL-1. 
KL-2; an alternatively spliced version of KL-1, lacks 
exon 6, which codes for the cleavage site found in KL-1. 
An alternative but much less efficient cleavage site exists 
in KL-2. As a consequence, the protein encoded by KL-2 
tends to remain cell-associated. Flanagan et al. (26) 
reported that the ratio of KL-1 to KL-2 mRNAs varied 
in different tissues, indicating that the alternative splicing 
event that creates them is regulated in a tissue-specific 
manner. They suggested that regulated alternative splic-
ing may provide a mechanism for the differential expres-
sion of the cell surface or soluble forms of SCF in different 
cells. To determine whether differential release of soluble 
SCF by hemangioma-derived and normal endothelial cells 
was due to alternative splicing, reverse transcriptase-
polymerase chain reaction (RT-PCR) techniques were 
used to identify the transcripts in these cells. Primers 
were designed to amplify a portion of the DNA sequence 
that included exon 6. The amplified segment of DNA was 
predicted to be 185 base pairs in length if exon 6 was 
present, and 101 base pairs in length if exon 6 was absent. 
Figure 6 illustrates the PCR products obtained by 
amplification of cDNA from BALB/c-3T3 fibroblasts 
(lane 1) as well as several hemangioma-derived endothe-
lial cells (lanes 2-4) and normal endothelial cells (lanes 
5 and 6). BALB/c-3T3 fibroblasts are known to express 
relatively large amounts of KL-1 (26) and were included 
as a positive control. Sl/Sld fibroblasts have a deletion 
in the SCF gene that removes the transmembrane and 
intracellular domains (26). These cells only produce a 
secreted form of SCF, which lacks a portion of the 
sequence amplified by our primers. Therefore, cDNA 
from these cells was included as a negative control*(farce 
7). A 185-base pair DNA fragment was amplified in 3T3 
cells and represents the KL-1 transcript. No 101-base 
pair fragment was amplified, indicating the absence of 
the the KL-2 transcript. This finding supports the 
Northern analysis data that demonstrated only a single 
SCF mRNA (Fig. 5). Sl/Sld fibroblasts did not exhibit 
either PCR product as expected. The larger molecular 
weight bands in farce 8 represent genomic DNA evident 
in control tubes containing no reverse transcriptase (i.e., 
samples in which cDNA could not be synthesized from 
the RNA [data not shown]). The same 185-base pair 
fragment amplified in the 3T3 fibroblasts was amplified 
in three different hemangioma-derived endothelial cell 
lines: the spontaneous EOMA cells (lane 2) as well as 
the retrovirus-induced Py4-1 (lane 3) and bEnd cells 
(lane 4). These data suggest that the production of SCF 
is a general property of hemangiomas and not just a 
property of the EOMA cells. In addition, the same tran-
script was identified in aortic (lane 5), lung (lane 6), and 
brain (data not shown) endothelial cells, indicating that 
this is a general property of endothelial cells, both large 
vessel and microvascular in origin. Finally, RT-PCR 
techniques were also used with human microvascular 
endothelial cells and primers specific for the human SCF 
sequence. The larger KL-1 sequence was amplified in 
these cells as well (data not shown), indicating that 
production of SCF is not just a property of murine 
endothelial cells. However, a small amount of the KL-2 
cDNA was also amplified in the human cells, which was 
not evident in the murine endothelial cells. 
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FIG. 6. Polymerase chain reaction (PCR) amplification of SCF 
cDNAs from hemangioma-derived and normal endothelial cells. PCR 
was performed on first strand cDNA prepared using reverse transcrip-
tase and total RNA from (a) BALB/c-3T3 fibroblasts, (b) EOMA cells, 
(c) Py4-1 cells, (d) bEnd cells, (e) murine aortic endothelial cells, (f) 
murine lung microvascular endothelial cells, and (g) Sl/Sld fibroblasts. 
The PCR products were separated on an 8% polyacrylamide gel under 
nondenaturing conditions. DNA bands were demonstrated by silver 
staining. A DNA ladder, included in lane 8, indicates the migration of 
DNA fragments in 100-base pair increments (100, 200, 300 base pairs, 
etc.) 
Angiogenesis is the process by which new capillaries 
are formed from preexisting blood vessels. Endothelial 
cells respond to angiogenic stimuli by producing pro-
teases to degrade their investing basement membrane 
and surrounding matrix. The endothelial cells then mi-
grate into the interstitium and proliferate to form 
sprouts. The anastomosis of two sprouts generates new 
capillary loops through which blood may flow. Expres-
sion of the polyoma virus middle T (mT) oncogene 
severely perturbs the ability of endothelial cells to form 
normal vascular structures. Infection of mice with a 
retrovirus carrying the mT oncogene results in the rapid 
formation of cavernous hemangiomas (27). These he-
mangiomas provide a source of stable endothelioma 
(End) cell lines that retain specific endothelial cell mark-
ers and express mT antigen. Injection of these cells into 
mice results in the rapid formation of hemangiomas, 
which demonstrates that these cells are the primary 
cause of the lesions (28). Montesano et al. (29) demon-
strated that the brain End (bEnd) hemangioma cells 
exhibited increased production of urokinase-type plas-
minogen activator and decreased production of plasmin-
ogen activator inhibitors. If this excess proteolytic activ-
ity was neutralized by adding exogenous serine protease 
inhibitors, normal capillary-like tubules were formed by 
the cells. These findings suggest that the difference be-
tween hemangioma-forming endothelial cells and normal 
endothelial cells lies in their protease production. In-
creased protease production would provide the means for 
release of SCF by the hemangioma-derived endothelial 
cells that was diminished or absent in normal endothelial 
cells. Western blotting techniques were used to demon-
strate the presence of SCF in all endothelial cells tested 
in this study, whereas immunoprecipitation followed by 
Western blotting confirmed the release of SCF into the 
medium of the three different hemangioma-derived endo-
thelial cells and confirmed the absence of release into 
the medium of normal brain microvascular endothelial 
cells (data not shown). 
Hemangiomas are benign tumors made up of prolifer-
ating endothelial cells and capillaries and are found in 
children. Mast cells are observed in large numbers in 
these proliferating hemangiomas both in humans and in 
mice injected with EOMA cells (personal communica-
tion, Dr. Michael O'Reilly, Children's Hospital, Harvard 
Medical School, Boston). The presence of mast cells in 
hemangiomas has never been completely understood. 
The data presented in this study indicate that endothelial 
cells in the hemangioma release soluble SCF, which may 
act to recruit mast cells into the hemangioma (11). Once 
inside the tumor mass, the mast cells may also proliferate 
and degranulate in response to SCF (13, 30). Degranu-
lation with subsequent release of mast cell products, such 
as heparin, histamine, or tumor necrosis factor a may 
then stimulate the growth of the endothelial cells of the 
hemangioma (5). Thus, a two-way interaction between 
endothelial and mast cell products may account for the 
rapid growth seen with this tumor. 
METHODS 
REAGENTS 
Recombinant rat stem cell factor (rrSCF) and neutralizing 
antibodies for rrSCF were generously provided by Dr. Krisztina 
Zsebo, Amgen Inc., Thousand Oaks, CA. Polyclonal rabbit anti-
murine stem cell factor as well as recombinant murine interleu-
kin-3 (IL-3) were obtained from Genzyme (Cambridge, MA). 
One unit of IL-3 is defined as the amount required to support 
half-maximal tritiated thymidine incorporation by 2.5 X 103 
FDC-P2 cells in 100-/U cultures as described by Prestidge et al. 
(31). 
CELLS 
The spontaneous hemangioma, or EOMA, cells were the 
kind gift of Dr. Robert Auerbach, University of Wisconsin, 
Madison, WI. These endothelial cells (15) were originally de-
rived by Hoak et al. (32) from a mixed hemangioendothelioma 
arising spontaneously in a mouse. Py4-1 cells were generously 
provided by Dr. Victoria Bautch, University of North Carolina, 
Chapel Hill, NC. These endothelial cells were isolated from 
hemangiomas induced by expression of the polyoma early re-
gion gene in transgenic mice (33). They exhibit properties of 
differentiated endothelial cells but are tumorigenic when rein-
troduced into mice. Endothelioma cells isolated from primary 
murine brain endothelial cells (bEnd) infected with a middle T 
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antigen-expressing retrovirus (34) were obtained from Dr. Werner 
Risau, Max-Planck Institute, Bad Nauheim, Germany. These 
cells also represent a stable cell line exhibiting specific endo-
thelial cell markers. In contrast to the Py4-1 cells, they express 
only polyoma middle T.antigen. All cells were maintained in 
Dulbecco's modified Eagle's medium (DMEM) containing 10% 
fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium 
pyruvate, 100 IU/ml penicillin, and 100 /xg/ml streptomycin. 
BALB/C-3T3 fibroblasts (obtained from the American Type 
Culture Collection, Rockville, MD) and Sl/Sld fibroblasts 
(kindly provided by Dr. Alan Bernstein, Mount Sinai Hospital, 
Toronto, Canada) were cultured in the same medium. MAEC 
as well as brain and lung microvessel endothelial cells (also 
provided by Dr. Auerbach) were cultured under similar condi-
tions, although the microvascular cells required 20% FBS. 
Cultured bone marrow-derived mast cells (CMC) were iso-
lated from marrow washed from femurs of WBB6 mice. 
Briefly, femurs were dissected free of muscle and connective 
tissue, and the marrow cavity was rinsed two times with 1 ml 
of sterile Minimal Essential Medium a (MEMa, GIBCO Lab-
oratories, Grand Island, NY). The cells were pooled, centrifuged 
(200 g for 10 minutes), and resuspended at a concentration of 
1 to 5 X 10s cells/ml in MEMa containing 10% FBS, 10% 
pokeweed mitogen-stimulated spleen cell conditioned medium 
as a source of IL-3 (35), 7 X 10"6 M 2-mercaptoethanol (2-ME), 
2 mM L-glutamine, 100 IU/ml penicillin, and 100 ng/m\ strep-
tomycin. One half of the medium was replaced with fresh 
medium every 7 days. Only mast cells remain in culture after 
30 days, as determined by positive staining with alcian blue. 
Homozygous mutant W42/W42 mast cells were the generous 
gift of Dr. Alan Bernstein. These cells express a c-kit receptor 
that is deficient in tyrosine kinase activity. They were main-
tained in the same culture medium as the CMC and were 
passaged every 3 to 4 days to keep the cell density at approxi-
mately 5 X 105 cells/ml. 
CONDITIONED MEDIUM 
Conditioned medium used to stimulate mast cell proliferation 
was prepared by incubating cultures of EOMA or MAEC in 
serum-free MEMa for 24 hours. These conditioned media were 
collected, filtered, supplemented with FBS (to a final concen-
tration of 10%) and 2-ME (to 7 X 106 M) and added to target 
mast cells for proliferation assays as described below. For 
immunoprecipitation and Western analysis, the cells were 
grown in DMEM and supplemented as described above for 
culture. The media were collected, filtered, and immunoprecip-
itated with a polyclonal rabbit anti-murine SCF (see below). 
PROLIFERATION ASSAYS 
Four to 5000 CMC or W42 mutant mast cells were resus-
pended in fresh or conditioned medium (both containing 10% 
FBS and 7 X 10-6 M 2-ME [basal medium]) and plated in 96-
well tissue culture trays. In some experiments, the conditioned 
medium was also supplemented with murine IL-3. The mast 
cells were incubated for 72 hours at 37" C and counted in a 
hemacytometer. 
In the experiments involving neutralizing antibodies, condi-
tioned medium and medium containing rrSCF were incubated 
with polyclonal rabbit anti-rrSCF antibodies (Amgen, Inc.) for 
1 hour at 37" C before mast cells were added. The mast cells 
were incubated an additional 72 hours and counted as described 
above. 
IMMUNOPRECIPITATION AND WESTERN BLOT ANALYSIS 
Conditioned media were prepared and collected as described 
above. The conditioned media were precleared (1 hour, room 
temperature) using affinity purified rabbit immunoglobulin 
linked to Protein A-Sepharose (Pharmacia, Piscataway, NJ) 
and centrifuged. The samples were then immunoprecipitated 
overnight at 4" C using polyclonal rabbit anti-murine stem cell 
factor (Genzyme, Cambridge, MA) at a concentration of 2 ngj 
ml previously bound to Protein-A Sepharose. The Sepharose 
with bound SCF was collected by centrifugation, rinsed well 
with Tris-buffered saline (TBS, 10 mM Tris-HCl, pH 7.5, 0.15 
M NaCl) and boiled in SDS sample buffer lacking 2-ME to 
release the SCF. After boiling, 2-ME was added to the samples, 
which were loaded on a 9.5 to 16% SDS polyacrylamide gradient 
gel and run under standard denaturing conditions (Laemmli). 
Separated proteins were blotted to nitrocellulose using 25 mM 
Tris, pH 8.3, 192 mM glycine, 20% methanol, and 0.02% SDS 
in a wet transblot system (BioRad, Hercules, CA). The nitro-
cellulose was blocked with 3% gelatin in TBS and incubated 
with rabbit anti-murine SCF at a concentration of 5 Mg/ml in 
TBS with 0.1% Tween 20 (TTBS) and 1% gelatin for 2 hours 
at room temperature or overnight at 4° C. The nitrocellulose 
was washed six times (5 minutes each wash) in TTBS, incu-
bated with horseradish peroxidase-conjugated goat anti-rabbit 
IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD), 
and diluted 1:20,000 in TTBS with 1% gelatin for 1 hour at 
room temperature. The nitrocellulose was again washed six 
times in TTBS, drained briefly, and incubated in Enhanced 
Chemiluminescence (ECL, Amersham, Arlington Heights, IL) 
substrate reagent for 1 minute. The blot was wrapped in Saran 
Wrap™ and exposed to film (ECL Hyperfilm, Amersham, 
Arlington Heights, IL) for 1 to 2 minutes. The molecular 
weights of the immunodetected bands from conditioned media 
were compared to molecular weight standards. 
RNA Isolation. Poly A+ RNA (mRNA) was isolated from 1 
to 2 X 10' cells using the Poly ATtractR System (Promega 
Corp., Madison, WI). Briefly, cells were extracted in guanidine 
thiocyanate/SDS extraction buffer containing 2% 2-ME and 
sonicated for 15 to 30 seconds. Biotinylated oligo (dT) probe 
(2.5 fil of a 50-pmole//xl solution) was added to the RNA, mixed 
well, and incubated at 70° C for five minutes. The lysate was 
transferred to a sterile 15-ml Corex tube and centrifuged at 
12,000 X g for 10 minutes at room temperature to clear the 
homogenate of cell debris and precipitated proteins. The su-
pernatant was removed, added to a tube containing a suspen-
sion of streptavidin paramagenetic particles (in 0.5 mis of 0.5x 
(sodium chloride/sodium citrate) and mixed well. The mag-
netic particles with bound mRNA were immobilized with a 
magnet, and the supernatant was removed. The particles were 
washed four times with 0.1X SSC (1.5 ml per wash). After the 
final wash, the supernatant was removed, and the mRNA was 
eluted by suspending the magnetic particles in 1 ml of RNase-
free water. The particles were immobilized with a magnet, and 
the aqueous phase containing the mRNA was transferred to a 
sterile RNase-free tube. The RNA was concentrated by adding 
0.1 volume of 3 M sodium acetate (pH 5.2) and 2.5 volumes of 
ethanol and by incubating overnight at -70" C. The RNA was 
pelleted by centrifugation at 12,000 x g for 10 minutes at 4° C 
and resuspended in RNase-free deionized water at 1 to 2 fig/fil. 
Northern Hybridization. RNA samples were separated in 
0.8% agarose-formaldehyde gels using 40 mM MOPS (pH 7.0)/ 
10 mM sodium acetate/1 mM EDTA as the running buffer and 
running at 5 volts/cm for 4 hours. Three micrograms of mRNA" 
were denatured in 2.2 M formaldehyde/50% of formamide 
(v/v) and loaded per lane. RNA molecular weight markers 
were also included on the gel. The separated nucleic acids 
were transferred overnight to HybondR nylon membranes 
(Amersham, Arlington Heights, IL) by wicking with northern 
transfer solution reagent (Biotecx, Houston, TX). After trans-
fer, the positions of the RNA markers were marked on the 
membrane, and the nucleic acids were bound to the nylon by 
baking at 80° C for 2 hours in a vacuum oven. Membranes were 
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prehybridized in a low background hybridization solution (Bio-
tecx, Houston, TX) containing 1 M NaCl, 0.1% SDS, and IX 
blocking reagent (Biotecx, Houston, TX) for 1 hour at room 
temperature in a sealed bag. The prehybridization solution was 
removed and replaced with hybridization solution containing 
blocking reagent and a 32P-labeled cDNA probe (5 x 106 dpm/ 
ml of hybridization solution) for murine SCF (Oncogene Sci-
ence, Uniondale, NY). The hybridization reaction was carried 
out overnight at 42° C. The membrane was removed from the 
bag and washed at room temperature in l x SSC (20x SSC 
contains 3 M NaCl and 0.3 M sodium citrate, pH 7) and 0.1% 
SDS three times at room temperature for 7 minutes and three 
times at 55" C for 10 minutes. After washing, the filter was 
wrapped in Saran WrapR, exposed to Kodak X-Omat AR film 
at —70* C for 48 to 72 hours with an intensifying screen, and 
processed for autoradiography. 
Reverse Transcriptase-Polymerase Chain Reaction Amplifi-
cation, Total RNA was isolated from cells with TriSolv™ 
(Biotecx Laboratories, Houston, TX), and cDNA was generated 
using Superscript II™ (GIBCO/BRL, Gaithersburg, MD). For 
cDNA synthesis, 5 fig of total RNA in 13 p\ of diethylpyrocar-
bonate (DEPC)-treated water was incubated with 1 fd of 50 
ng/pl random hexamers, heated to 70* C for 10 minutes, and 
incubated for 1 minute on ice. Added to this mixture was 2 p\ 
of buffer (200 mM Tris-HCl [pH 8.4], 500 mM KC1, 25 mM 
MgCl2, 1 Mg//d bovine serum albumin), 1 pi of dNTP mixture 
(10 mM each of dATP, dCTP, dGTP and dTTP), 2 fd of 100 
mM DTT, and 1 pi of reverse transcriptase (200 U//d). The 
total mixture was incubated at room temperature for 10 min-
utes, at 42° C for 50 minutes, at 70" C for 15 minutes, and then 
placed on ice. Two units of RNase H were added, and the tube 
was incubated at 37° C for 20 minutes. The first strand cDNA 
generated by these methods was amplified directly by adding 
the following to the same tube: 8 pi of buffer (as above), 68 pi 
of sterile distilled water, 2 pi of amplification primer 1 (5 pM), 
2 pi of amplification primer 2 (5 piA), and 2 to 5 units of Taq 
polymerase (GIBCO/BRL). The primers used were: 5'-TGG-
TGGCATCTGACACTAGTGACTGT-3' and 5'-TGTCAAT-
TGTAGGCCCGAGTCTTCA-3'. The reaction mixture was 
heated to 94* C for 5 minutes to denature the RNA/cDNA 
hybrid, and polymerase chain reaction was carried out for 30 
cycles. The amplified DNA fragments were separated on an 8% 
polyacrylamide gel under nondenaturing conditions and were 
visualized by staining with silver stain (BioRad, Richmond, CA). 
Acknowledgments: This work was supported by N.I.H. 
Grants #CA45548 to B. R. Zetter and HL07782 to C. J. 
Meininger as well as a Grant-in-Aid (#91R-029) to C. J. 
Meininger from the American Heart Association, Texas 
Affiliate. 
Date of acceptance: August 30,1994. 
Address reprint requests to: Cynthia J. Meininger, Ph.D., Depart-
ment of Medical Physiology, Texas A&M University Health Science 
Center, Reynolds Medical Building Rm. 345, College Station, TX 
77843-1114. 
REFERENCES 
1. Cooper AG, Bolande RP. Multiple hemangiomas in an infant with 
cardiac hypertrophy. Pediatrics 1965;35:27-33. 
2. Ferguson CF, Flake CG. Subglottic hemangioma as a cause of 
respiratory obstruction in infants. Ann Otol Rhinol Laryngol 
1961;70:1095-112. 
3. Larcher VF, Howard ER, Mowat AP. Hepatic hemangiomas, 
diagnosis and treatment. Arch Dis Child 1981;56:7-14. 
4. Kasabach HH, Merritt KK. Capillary hemangioma with extensive 
purpura: Report of a case. Am J Dis Child 1940;59:1063-70. 
5. Glowacki J, Mulliken JB. Mast cells in hemangiomas and vascular 
malformations. Pediatrics 1982;70:48-51. 
6. Dethlefsen SM, Mulliken J, Glowacki J. An ultrastructural study 
of mast cell interactions in hemangiomas. Ultrastruc Pathol 
1986;10:175-183. 
7. Kessler DA, Langer RS, Pless NA, Folkman J. Mast cells and 
tumor angiogenesis. Int J Cane 1976;18:703-9. 
8. Poole TJ, Zetter BR. Stimulation of rat peritoneal mast cell migra-
tion by tumor-derived peptides. Can Res 1983;43:5857-61. 
9. Thompson HL, Burbelo PD, Yamada Y, Kleinman HK, Metcalfe 
DD. Mast cells chemotax to laminin with enhancement after IgE-
mediated activation. J Immunol 1989;143:4188-92. 
10. Matsuura N, Zetter BR. Stimulation of mast cell chemotaxis by 
interleukin 3. J Exp Med 1989;170:1421-6. 
11. Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo K, Zetter 
BR. The c-kit receptor ligand is a chemoattractant for mast cells. 
Blood 1992;79:958-63. 
12. Zsebo KM, Wypych J, McNiece IK, Lu KS, Smith KA, Karkare 
SB, et al. Identification, purification and biological characteriza-
tion of hematopoietic stem cell factor from Buffalo rat liver-
conditioned medium. Cell 1990;63:195-201. 
13. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, 
Rauch C, et al. Molecular cloning of mast cell growth factor, a 
hematopoietin that is active in both membrane bound and soluble 
forms. Cell 1990;63:235-43. 
14. Huang E, Nocka K, Beier DR, Chu T, Buck J, Lahm H, et al. The 
hematopoietic growth factor KL is encoded by the Steel locus and 
is the ligand of the c-kit receptor, the gene product of the W locus. 
Cell 1990;63:225-33. 
15. Obeso J, Weber J, Auerbach R. A hemangioendothelioma-derived 
cell line: Its use as a model for the study of endothelial cell biology. 
Lab Invest 1990;63:259-69. 
16. Martin RH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, 
RK, et al. Primary structure and functional expression of rat and 
human stem cell factor DNAs. Cell 1990;63:203-12. 
17. Huang EJ, Nocka KH, Buck J, Besmer P. Differential expression 
and processing of two cell associated forms of the kit-ligand: KL-
1 and KL-2. Mol Biol Cell 1992;3:349-62. 
18. Pandiella A, Bosenberg MW, Huang EJ, Besmer P, Massague J. 
Cleavage of membrane-anchored growth factors involves distinct 
protease activities regulated through common mechanisms. J Biol 
Chem 1992;267:24028-33. 
19. Lu HS, Clogston CL, Wypych J, Fausset PR, Lauren S, Mendiaz 
EA, et al. Amino acid sequence and post-translational modification 
of stem cell factor isolated from buffalo rat liver cell-conditioned 
medium. J Biol Chem 1991;266:8102-7. 
20. Arakawa T, Ypljantis DA, Lary JW, Narhi LO, Lu HS, et al. 
Glycosylated and unglycosylated recombinant-derived human stem 
cell factors are dimeric and have extensive secondary structure. J 
Biol Chem 1991;266:18942-8. 
21. Aye MT, Hashemi S, Leclair B, Zeibdawi A, Trudel E, Halpenny 
M, Fuller V, Cheng G. Expression of stem cell factor and c-kit 
mRNA in cultured endothelial cells, monocytes and cloned human 
bone marrow stromal cells (CFU-RF). Exp Hematol 1992;20: 
523-7. 
22. Bazan JF. Genetic and structural homology of stem cell factor and 
macrophage colony-stimulating factor. Cell 1991;65:9-10. 
23. Rettenmier CW, Roussel MF, Ashmun RA, Ralph P, Price K, 
Sherr CJ. Synthesis of membrane bound colony stimulating factor 
1 (CSF-1) and downmodulation of CSF-1 receptors in NIH 3T3 
cells transformed by cotransfection of the human CSF-1 and c-fms 
(CSF-1) receptor genes. Mol Cell Biol 1987;7:2378-87. 
24. Rettenmier CW, Roussel MF. Differential processing of colony-
stimulating factor 1 precursors encoded by two human cDNAs. 
Mol Cell Biol 1988;8:5026-34. 
25. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of 
TNF/cachectin is a cell surface cytotoxic transmembrane protein: 
Ramifications for the complex physiology of TNF. Cell 1988;53: 
45-53. 
26. Flanagan JG, Chan DC, Leder P. Transmembrane form of the kit 
ligand growth factor is determined by alternative splicing and is 
missing in the St* mutant. Cell 1991;64:1024-35. 
27. Williams RL, Courtneidge SA, Wagner EF. Embryonic lethalities 
and endothelial tumors in chimeric mice expressing polyoma virus 
middle T oncogene. Cell 1988;52:121-31. 
28. Williams RL, Risau W, Zerwes H-G, Drexler H, Aguzzi A, Wagner 
EF. Endothelioma cells expressing the polyoma middle T oncogene 
4 
ol.'-72fNo. 2, 1995 ENDOTHELIAL RELEASE OF STEM CELL FACTOR 173 
h . induce hemangiomas by host cell recruitment. Cell 1989;57: mangioma with thrombocytopenia and microangiopathic anemia 
" 1053-63. (Kasabach-Merritt syndrome: An animal model). J Lab Clin Med 
29. Montesano R, Pepper MS, Mohle-Steinlein U, Risau W, Wagner 1971;77:941-50. 
EF, Orci L. Increased proteolytic activity is responsible for the 33. Dubois NA, Kolpack LC, Wang R, Azizkhan RG, Bautch VL. 
aberrant morphogenetic behavior of endothelial cells expressing Isolation and characterization of an established endothelial cell 
the middle T oncogene. Cell 1990;62:435-45. line from transgenic mouse hemangiomas. Exp Cell Res 
30. Nakajima K, Hirai K, Yamaguchi M, Takaishi T, Ohta K, Morita 1991;196:302-13. 
Y, Ito K. Stem cell factor has histamine releasing activity in rat 34. Montesano R, Pepper MS, Mohle-Steinlein U, Risau W, Wagner 
connective tissue-type mast cells. Biochem Biophys Res Commun EF, Orci L. Increased proteolytic activity is responsible for the 
1992;183:1076-83. aberrant morphogenetic behavior of endothelial cells "expressing 
31. Prestidge RL, Watson JD, Urdal DL, Michizuki D, Conlon P, Gillis the middle T oncogene. Cell 1990;62:435-45. 
S. Biochemical comparison of murine colony-stimulating factors 35. Nakahata T, Ogawa M. Identification in culture of a class of 
secreted by a T cell lymphoma and myelomonocytic leukemia. J hematopoietic colony-forming units with extensive capability to 
Immunol 1984;133:293-8. self-renew and generate multipotential hematopoietic colonies. 
32. Hoak JC, Warner ED, Cheng HF, Fry GL, Hankenson RR. He- Proc Natl Acad Sci USA 1982;79:3843-7. 
